Market Cap 2.82B
Revenue (ttm) 451.36M
Net Income (ttm) -66.42M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -14.72%
Debt to Equity Ratio 0.21
Volume 1,785,600
Avg Vol 814,782
Day's Range N/A - N/A
Shares Out 43.02M
Stochastic %K 69%
Beta 0.50
Analysts Strong Sell
Price Target $90.56

Company Profile

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites. It sells its products to specialty pharmacies and distributors, as well as clinics, hospitals, pharmacies, and federal healthcare programs. The company also develops TP-0...

Industry: Biotechnology
Sector: Healthcare
Phone: 949 418 1801
Address:
17700 Laguna Canyon Road, Floor 4, Irvine, United States
AXLFI_HQ
AXLFI_HQ Jul. 4 at 12:41 PM
The most recent Sustained Momentum signal on $TARS triggered on 2026-07-02. The expected return for the selected horizon is +21.68% with a historical profit probability of +61.54%. Learn more: https://axlfi.com/factor-analysis?symbol=TARS&factor=sus_momentum&timeframe=daily
0 · Reply
NJgolfer
NJgolfer Jul. 3 at 9:39 PM
$TARS major move this week. On only 4 days trading volume, rose 4% on volume that was 2.15X larger than normal. Crossed above all major weekly EMAs and most importantly 21w EMA. Broke downtrend resisttance that was in place since Dec 2024.
0 · Reply
JFais
JFais Jul. 3 at 1:33 PM
0 · Reply
Biotechace
Biotechace Jul. 3 at 1:02 PM
$TARS Cuck Culper posting they had someone obtain a script for Xdemvy through an online doctor and the person didn't have demodex mites. Wouldn't the crime in itself be lying to the online doctor to obtain a prescription you didn't need? Maybe they need to be investigated?
0 · Reply
bentley99
bentley99 Jul. 3 at 2:37 AM
$VRDN Sorry I'm late. Love AI search. $OMER and $ABEO folks see this and $TARS
1 · Reply
Mondose
Mondose Jul. 2 at 11:40 PM
$TARS Don’t give the bogus co-pay hit report any credence. About co-pay assistance, pharma doing this for specialty/branded drugs is widespread and routine: - ASHP notes that many patients rely on copay cards from manufacturers, especially for specialty and brand‑name medications with high out‑of‑pocket costs. - Drug Channels reports that brand‑name manufacturers routinely provide copay offset programs and patient assistance programs (PAPs) to soften high deductibles for specialty drugs. - NASTAD highlights that manufacturers maintain numerous patient assistance and cost‑sharing programs, updated annually, for branded drugs in high‑cost therapeutic areas. These sources collectively show that copay assistance is not an exception — it’s the norm. These are my opinions only and not investment advice.
0 · Reply
STACKD0E
STACKD0E Jul. 2 at 9:37 PM
0 · Reply
4Reel
4Reel Jul. 2 at 9:10 PM
$TARS ah action, boom short report blown out of the water
0 · Reply
Biotechace
Biotechace Jul. 2 at 8:34 PM
$TARS I wonder how Cuck Culper is enjoying the premium bleed out on his puts today?
0 · Reply
Biotechace
Biotechace Jul. 2 at 7:45 PM
$TARS I wonder how Cuck Culper is enjoying their short position? Maybe Cuck won't be able to afford a frozen burrito at 7-Eleven after the dust settles.
0 · Reply
Latest News on TARS
Tarsus to Participate in Upcoming Investor Conferences

May 28, 2026, 4:30 PM EDT - 5 weeks ago

Tarsus to Participate in Upcoming Investor Conferences


Tarsus Pharmaceuticals reports Q1 EPS (16c), consensus (40c)

2026-05-07T00:43:07.000Z - 2 months ago

Tarsus Pharmaceuticals reports Q1 EPS (16c), consensus (40c)


Tarsus Pharmaceuticals Earnings Call Transcript: Q1 2026

May 6, 2026, 4:30 PM EDT - 2 months ago

Tarsus Pharmaceuticals Earnings Call Transcript: Q1 2026


Tarsus Pharmaceuticals Earnings release: Q1 2026

May 6, 2026, 4:30 PM EDT - 2 months ago

Tarsus Pharmaceuticals Earnings release: Q1 2026


Tarsus Pharmaceuticals Quarterly report: Q1 2026

May 6, 2026, 4:30 PM EDT - 2 months ago

Tarsus Pharmaceuticals Quarterly report: Q1 2026


Tarsus Pharmaceuticals Slides: Q1 2026

May 6, 2026, 4:30 PM EDT - 2 months ago

Tarsus Pharmaceuticals Slides: Q1 2026


Tarsus Pharmaceuticals Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 2 months ago

Tarsus Pharmaceuticals Proxy statement: Proxy filing


Tarsus Pharmaceuticals Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 2 months ago

Tarsus Pharmaceuticals Proxy statement: Proxy filing


Tarsus Pharmaceuticals doses first participant in TP-05 trial

2026-03-31T14:23:18.000Z - 3 months ago

Tarsus Pharmaceuticals doses first participant in TP-05 trial


Tarsus Pharmaceuticals rises 11.6%

2026-02-24T15:07:40.000Z - 4 months ago

Tarsus Pharmaceuticals rises 11.6%


Tarsus Pharmaceuticals Earnings Call Transcript: Q4 2025

Feb 23, 2026, 4:30 PM EST - 4 months ago

Tarsus Pharmaceuticals Earnings Call Transcript: Q4 2025


Tarsus Pharmaceuticals Annual report: Q4 2025

Feb 23, 2026, 4:30 PM EST - 4 months ago

Tarsus Pharmaceuticals Annual report: Q4 2025


Tarsus Pharmaceuticals Earnings release: Q4 2025

Feb 23, 2026, 4:30 PM EST - 4 months ago

Tarsus Pharmaceuticals Earnings release: Q4 2025


Tarsus Pharmaceuticals Slides: Q4 2025

Feb 23, 2026, 4:30 PM EST - 4 months ago

Tarsus Pharmaceuticals Slides: Q4 2025


Tarsus Pharmaceuticals reports Q4 EPS (20c), consensus (13c)

2026-02-23T21:25:00.000Z - 4 months ago

Tarsus Pharmaceuticals reports Q4 EPS (20c), consensus (13c)


Tarsus Pharmaceuticals appoints Pyott to Board of Directors

2026-02-18T13:46:13.000Z - 4 months ago

Tarsus Pharmaceuticals appoints Pyott to Board of Directors


Tarsus Pharmaceuticals initiated with an Overweight at Barclays

2025-12-08T21:30:53.000Z - 7 months ago

Tarsus Pharmaceuticals initiated with an Overweight at Barclays


Tarsus Pharmaceuticals initiated with an Outperform at Mizuho

2025-11-20T10:45:19.000Z - 8 months ago

Tarsus Pharmaceuticals initiated with an Outperform at Mizuho


Tarsus Pharmaceuticals Earnings Call Transcript: Q3 2025

Nov 4, 2025, 4:30 PM EST - 8 months ago

Tarsus Pharmaceuticals Earnings Call Transcript: Q3 2025


Tarsus Pharmaceuticals Quarterly report: Q3 2025

Nov 4, 2025, 4:30 PM EST - 8 months ago

Tarsus Pharmaceuticals Quarterly report: Q3 2025


Tarsus Pharmaceuticals Earnings release: Q3 2025

Nov 4, 2025, 4:30 PM EST - 8 months ago

Tarsus Pharmaceuticals Earnings release: Q3 2025


Tarsus Pharmaceuticals Slides: Q3 2025

Nov 4, 2025, 4:30 PM EST - 8 months ago

Tarsus Pharmaceuticals Slides: Q3 2025


Tarsus Pharmaceuticals reports Q3 EPS (30c), consensus (33c)

2025-11-04T21:15:37.000Z - 8 months ago

Tarsus Pharmaceuticals reports Q3 EPS (30c), consensus (33c)


Tarsus Pharmaceuticals Earnings Call Transcript: Q2 2025

Aug 6, 2025, 4:30 PM EDT - 11 months ago

Tarsus Pharmaceuticals Earnings Call Transcript: Q2 2025


Tarsus Pharmaceuticals Quarterly report: Q2 2025

Aug 6, 2025, 4:30 PM EDT - 11 months ago

Tarsus Pharmaceuticals Quarterly report: Q2 2025


Tarsus Pharmaceuticals Earnings release: Q2 2025

Aug 6, 2025, 4:30 PM EDT - 11 months ago

Tarsus Pharmaceuticals Earnings release: Q2 2025


Tarsus Pharmaceuticals Slides: Q2 2025

Aug 6, 2025, 4:30 PM EDT - 11 months ago

Tarsus Pharmaceuticals Slides: Q2 2025


Tarsus Pharmaceuticals Earnings Call Transcript: Q1 2025

May 1, 2025, 4:30 PM EDT - 1 year ago

Tarsus Pharmaceuticals Earnings Call Transcript: Q1 2025


Tarsus Pharmaceuticals Quarterly report: Q1 2025

May 1, 2025, 4:30 PM EDT - 1 year ago

Tarsus Pharmaceuticals Quarterly report: Q1 2025


Tarsus Pharmaceuticals Earnings release: Q1 2025

May 1, 2025, 4:30 PM EDT - 1 year ago

Tarsus Pharmaceuticals Earnings release: Q1 2025


Tarsus Pharmaceuticals Slides: Q1 2025

May 1, 2025, 4:30 PM EDT - 1 year ago

Tarsus Pharmaceuticals Slides: Q1 2025


Tarsus Pharmaceuticals Slides: Corporate Presentation

May 1, 2025, 3:00 PM EDT - 1 year ago

Tarsus Pharmaceuticals Slides: Corporate Presentation


Tarsus Pharmaceuticals Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Tarsus Pharmaceuticals Proxy statement: Proxy Filing


Tarsus Pharmaceuticals Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Tarsus Pharmaceuticals Proxy statement: Proxy Filing


Tarsus Announces Proposed $100.0 Million Public Offering

Mar 12, 2025, 4:12 PM EDT - 1 year ago

Tarsus Announces Proposed $100.0 Million Public Offering


Tarsus to Participate in Upcoming Investor Conference

Mar 6, 2025, 5:00 PM EST - 1 year ago

Tarsus to Participate in Upcoming Investor Conference


Tarsus Pharmaceuticals Earnings Call Transcript: Q4 2024

Feb 25, 2025, 8:00 AM EST - 1 year ago

Tarsus Pharmaceuticals Earnings Call Transcript: Q4 2024


Tarsus Pharmaceuticals Annual report: Q4 2024

Feb 25, 2025, 8:00 AM EST - 1 year ago

Tarsus Pharmaceuticals Annual report: Q4 2024


Tarsus Pharmaceuticals Earnings release: Q4 2024

Feb 25, 2025, 8:00 AM EST - 1 year ago

Tarsus Pharmaceuticals Earnings release: Q4 2024


Tarsus Pharmaceuticals Slides: Q4 2024

Feb 25, 2025, 8:00 AM EST - 1 year ago

Tarsus Pharmaceuticals Slides: Q4 2024


Tarsus Pharmaceuticals Transcript: Investor Update

Jan 14, 2025, 11:00 AM EST - 1 year ago

Tarsus Pharmaceuticals Transcript: Investor Update


Tarsus Pharmaceuticals Press release: Investor Update

Jan 14, 2025, 11:00 AM EST - 1 year ago

Tarsus Pharmaceuticals Press release: Investor Update


Tarsus Pharmaceuticals Slides: Investor Update

Jan 14, 2025, 11:00 AM EST - 1 year ago

Tarsus Pharmaceuticals Slides: Investor Update


Tarsus Pharmaceuticals Earnings Call Transcript: Q3 2024

Nov 13, 2024, 4:30 PM EST - 1 year ago

Tarsus Pharmaceuticals Earnings Call Transcript: Q3 2024


Tarsus Pharmaceuticals Quarterly report: Q3 2024

Nov 13, 2024, 4:30 PM EST - 1 year ago

Tarsus Pharmaceuticals Quarterly report: Q3 2024


Tarsus Pharmaceuticals Earnings release: Q3 2024

Nov 13, 2024, 4:30 PM EST - 1 year ago

Tarsus Pharmaceuticals Earnings release: Q3 2024


Tarsus Pharmaceuticals Earnings Call Transcript: Q2 2024

Aug 8, 2024, 4:30 PM EDT - 2 years ago

Tarsus Pharmaceuticals Earnings Call Transcript: Q2 2024


Tarsus Pharmaceuticals Quarterly report: Q2 2024

Aug 8, 2024, 4:30 PM EDT - 2 years ago

Tarsus Pharmaceuticals Quarterly report: Q2 2024


Tarsus Pharmaceuticals Earnings release: Q2 2024

Aug 8, 2024, 4:30 PM EDT - 2 years ago

Tarsus Pharmaceuticals Earnings release: Q2 2024


Tarsus Pharmaceuticals Earnings Call Transcript: Q1 2024

May 8, 2024, 4:30 PM EDT - 2 years ago

Tarsus Pharmaceuticals Earnings Call Transcript: Q1 2024


Tarsus Pharmaceuticals Quarterly report: Q1 2024

May 8, 2024, 4:30 PM EDT - 2 years ago

Tarsus Pharmaceuticals Quarterly report: Q1 2024


Tarsus Pharmaceuticals Earnings release: Q1 2024

May 8, 2024, 4:30 PM EDT - 2 years ago

Tarsus Pharmaceuticals Earnings release: Q1 2024


Tarsus Pharmaceuticals Proxy statement: Proxy Filing

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Tarsus Pharmaceuticals Proxy statement: Proxy Filing


Tarsus Pharmaceuticals Proxy statement: Proxy Filing

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Tarsus Pharmaceuticals Proxy statement: Proxy Filing


Tarsus to Participate at Upcoming Investor Conferences

Mar 5, 2024, 4:30 PM EST - 2 years ago

Tarsus to Participate at Upcoming Investor Conferences


Tarsus Announces Pricing of $100.0 Million Public Offering

Mar 1, 2024, 12:07 AM EST - 2 years ago

Tarsus Announces Pricing of $100.0 Million Public Offering


Tarsus Pharmaceuticals Earnings Call Transcript: Q4 2023

Feb 27, 2024, 8:00 AM EST - 2 years ago

Tarsus Pharmaceuticals Earnings Call Transcript: Q4 2023


Tarsus Pharmaceuticals Annual report: Q4 2023

Feb 27, 2024, 8:00 AM EST - 2 years ago

Tarsus Pharmaceuticals Annual report: Q4 2023


Tarsus Pharmaceuticals Earnings release: Q4 2023

Feb 27, 2024, 8:00 AM EST - 2 years ago

Tarsus Pharmaceuticals Earnings release: Q4 2023


Tarsus Pharmaceuticals Earnings Call Transcript: Q3 2023

Nov 9, 2023, 4:30 PM EST - 2 years ago

Tarsus Pharmaceuticals Earnings Call Transcript: Q3 2023


Tarsus Pharmaceuticals Quarterly report: Q3 2023

Nov 9, 2023, 4:30 PM EST - 2 years ago

Tarsus Pharmaceuticals Quarterly report: Q3 2023


Tarsus Pharmaceuticals Earnings release: Q3 2023

Nov 9, 2023, 4:30 PM EST - 2 years ago

Tarsus Pharmaceuticals Earnings release: Q3 2023


Tarsus to Present at Upcoming Investor Conferences

Aug 30, 2023, 4:30 PM EDT - 3 years ago

Tarsus to Present at Upcoming Investor Conferences


Tarsus Pharmaceuticals Quarterly report: Q2 2023

Aug 10, 2023, 7:00 AM EDT - 3 years ago

Tarsus Pharmaceuticals Quarterly report: Q2 2023


Tarsus Pharmaceuticals Earnings release: Q2 2023

Aug 10, 2023, 7:00 AM EDT - 3 years ago

Tarsus Pharmaceuticals Earnings release: Q2 2023


Tarsus Pharmaceuticals Transcript: FDA Announcement

Jul 25, 2023, 8:30 AM EDT - 3 years ago

Tarsus Pharmaceuticals Transcript: FDA Announcement


Tarsus Pharmaceuticals Press release: FDA Announcement

Jul 25, 2023, 8:30 AM EDT - 3 years ago

Tarsus Pharmaceuticals Press release: FDA Announcement


Tarsus Pharmaceuticals Slides: FDA Announcement

Jul 25, 2023, 8:30 AM EDT - 3 years ago

Tarsus Pharmaceuticals Slides: FDA Announcement


Tarsus Pharmaceuticals Transcript: Status Update

Jun 15, 2023, 11:30 AM EDT - 3 years ago

Tarsus Pharmaceuticals Transcript: Status Update


Tarsus Pharmaceuticals Slides: Status Update

Jun 15, 2023, 11:30 AM EDT - 3 years ago

Tarsus Pharmaceuticals Slides: Status Update


AXLFI_HQ
AXLFI_HQ Jul. 4 at 12:41 PM
The most recent Sustained Momentum signal on $TARS triggered on 2026-07-02. The expected return for the selected horizon is +21.68% with a historical profit probability of +61.54%. Learn more: https://axlfi.com/factor-analysis?symbol=TARS&factor=sus_momentum&timeframe=daily
0 · Reply
NJgolfer
NJgolfer Jul. 3 at 9:39 PM
$TARS major move this week. On only 4 days trading volume, rose 4% on volume that was 2.15X larger than normal. Crossed above all major weekly EMAs and most importantly 21w EMA. Broke downtrend resisttance that was in place since Dec 2024.
0 · Reply
JFais
JFais Jul. 3 at 1:33 PM
0 · Reply
Biotechace
Biotechace Jul. 3 at 1:02 PM
$TARS Cuck Culper posting they had someone obtain a script for Xdemvy through an online doctor and the person didn't have demodex mites. Wouldn't the crime in itself be lying to the online doctor to obtain a prescription you didn't need? Maybe they need to be investigated?
0 · Reply
bentley99
bentley99 Jul. 3 at 2:37 AM
$VRDN Sorry I'm late. Love AI search. $OMER and $ABEO folks see this and $TARS
1 · Reply
Mondose
Mondose Jul. 2 at 11:40 PM
$TARS Don’t give the bogus co-pay hit report any credence. About co-pay assistance, pharma doing this for specialty/branded drugs is widespread and routine: - ASHP notes that many patients rely on copay cards from manufacturers, especially for specialty and brand‑name medications with high out‑of‑pocket costs. - Drug Channels reports that brand‑name manufacturers routinely provide copay offset programs and patient assistance programs (PAPs) to soften high deductibles for specialty drugs. - NASTAD highlights that manufacturers maintain numerous patient assistance and cost‑sharing programs, updated annually, for branded drugs in high‑cost therapeutic areas. These sources collectively show that copay assistance is not an exception — it’s the norm. These are my opinions only and not investment advice.
0 · Reply
STACKD0E
STACKD0E Jul. 2 at 9:37 PM
0 · Reply
4Reel
4Reel Jul. 2 at 9:10 PM
$TARS ah action, boom short report blown out of the water
0 · Reply
Biotechace
Biotechace Jul. 2 at 8:34 PM
$TARS I wonder how Cuck Culper is enjoying the premium bleed out on his puts today?
0 · Reply
Biotechace
Biotechace Jul. 2 at 7:45 PM
$TARS I wonder how Cuck Culper is enjoying their short position? Maybe Cuck won't be able to afford a frozen burrito at 7-Eleven after the dust settles.
0 · Reply
SmartCapitall
SmartCapitall Jul. 2 at 7:18 PM
Was there a short report on $TARS? I was looking at it long for good reason, but the short thesis has merit. Still, someone may want to buy here. It all comes down to price.
2 · Reply
MysticChartReaderIQ69
MysticChartReaderIQ69 Jul. 2 at 5:05 PM
$TARS the short report is interesting , not sure the prevalence of manufactures covering copays.
0 · Reply
CH_Expat
CH_Expat Jul. 2 at 4:28 PM
$TARS The short report scared the core investors to death obviously.
0 · Reply
Biotechace
Biotechace Jul. 2 at 1:33 PM
$TARS will TARS come out with a statement regarding Cuck Culper's report or will they simply stay silent?
2 · Reply
CH_Expat
CH_Expat Jul. 2 at 5:46 AM
$MLYS $CRNX $TARS $IDYA I was finally able to open positions in all stocks I wanted for averages I can live with. All of those were not part of the XBI-Surge.
0 · Reply
4Reel
4Reel Jul. 2 at 12:36 AM
$TARS there is only 5m shares short from the fully ownedtute float. And theres been 5m about every 2 weeks when announced so nothing has changed this entire year. This was clear market manipulation. And as u can see revenue has been increasing at a good pace. Over double from last year. If its so bad how come the entire float us tute owned?
0 · Reply
Vakeshka
Vakeshka Jul. 1 at 10:21 PM
$TARS full disclosure: I have no positions in this stock; in fact, did not know about this company until heard about the Culper short report. I'm a long-term AXSM shareholder. On June 11, 2024 Culper issued a short report on Axsome stating the company improperly inflated its revenues. The stock immediately dropped over 10% from the prior day's close. It was scary in the moment, but I still went ahead and added 17 shares at $66-69. See the attached snippet - up on those shares 250%+... of course, now wish picked up 1,700 shares that day :-) I don't how how valid Culper's report re Tarsus, but wanted to share a personal data point.
1 · Reply
Creyedr
Creyedr Jul. 1 at 9:36 PM
$TARS ignore the noise. This company and stock can’t be stopped. So your research on Culper. If anything isn’t kosher, it’s not tarsus. I hope the company countersues.
1 · Reply
OpenOutcrier
OpenOutcrier Jul. 1 at 8:02 PM
RECAP 7/1 +Pos Comments: $MBGL + Juber Research $EAF + Odeon $MU + Trump $SPGI + Huber Research RECAP 7/1 -Neg Comments: $TARS - Culper Research $STZ - Freedom Broker Live Breaking trading news www.openoutcrier.com
1 · Reply
WallStreetRadar
WallStreetRadar Jul. 1 at 7:54 PM
$TARS short thesis is clear: XDEMVY looks propped up by a copay structure that raises anti-kickback risk, the real TAM may be much smaller than the market assumes, and FY26 numbers could miss. Tissue looks fragile here.
2 · Reply
BarbaraSmith247
BarbaraSmith247 Jul. 1 at 7:53 PM
$TARS short thesis is clear: XDEMVY looks propped up by a copay structure that raises anti-kickback risk, the real TAM may be much smaller than the market assumes, and FY26 numbers could miss. Tissue looks fragile here.
1 · Reply
StocktwitsNews
StocktwitsNews Jul. 1 at 7:28 PM
TARS Stock Drops After Culper Research Accuses Tarsus Of Illegal Medicare Copay Scheme $TARS $AXSM $PRAX $VTI $IWM https://stocktwits.com/news/equity/markets/tars-stpock-drops-after-culper-research-accuses-tarsus-of-illegal-medicare-copay-scheme/cZm3nSfR71g
1 · Reply